Safety and Tolerability of Single and Multiple Doses of Neumifil

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

April 5, 2022

Study Completion Date

April 5, 2022

Conditions
Viral Respiratory Tract Infection
Interventions
DRUG

Neumifil

Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.

DRUG

Placebo

Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research (HMR), London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pneumagen Ltd.

INDUSTRY